Rockwell Medical,Inc. (NASDAQ:RMTI) Files An 8-K Other Events
Item 8.01 Other Events
On April4, 2017, Rockwell Medical,Inc. (the Company)
issued a press release announcing that it had filed a preliminary
proxy statement with the Securities and Exchange Commission for
the election of David Domzalski to the Companys Board of
Directors at the Companys 2017 Annual Meeting of Shareholders,
and announcing certain corporate governance enhancements.
Attached hereto as Exhibit99.1, and incorporated herein by
reference, is a copy of the press release.
Item 9.01 Financial Statements and
Exhibits
|
ExhibitNumber |
|
Description |
|
99.1 |
Rockwell Medical,Inc. Press Release issued on April4, 2017 |
Important Additional Information and Where to Find
It
Rockwell Medical,Inc., its directors and certain of its executive
officers may be deemed to be participants in the solicitation of
proxies from the Companys shareholders in connection with the
matters to be considered at the 2017 Annual Meeting of
Shareholders. Information regarding the names of the Companys
directors and executive officers and their respective direct or
indirect interests in the Company, by security holdings or
otherwise, can be found in the Companys preliminary proxy
statement for its 2017 Annual Meeting of Shareholders, including
the schedules and appendices thereto. The preliminary proxy
statement was filed with the Securities and Exchange Commission
(SEC) on April4, 2017. Investors and shareholders
are strongly encouraged to read carefully the definitive proxy
statement and the accompanying WHITE proxy card and any
other documents filed by Rockwell Medical,Inc. with the SEC when
they become available, as they will contain important
information. Shareholders will be able to obtain the
definitive proxy statement, any amendments or supplements to the
definitive proxy statement, the accompanying WHITE proxy card,
and other documents filed by Rockwell Medical,Inc. with the SEC
for no charge at the SECs website at www.sec.gov. Copies will
also be available at no charge by writing to Rockwell
Medical,Inc., Attn: Secretary, 30142 S. Wixom Road, Wixom,
Michigan, 48393.
About Rockwell Medical, Inc. (NASDAQ:RMTI)
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products. Rockwell Medical, Inc. (NASDAQ:RMTI) Recent Trading Information
Rockwell Medical, Inc. (NASDAQ:RMTI) closed its last trading session up +0.10 at 6.33 with 398,755 shares trading hands.